ORFeus Decoding the dark proteome through interdisciplinary training and research
- Coordinator
- Prinses Maxima Centrum Voor Kinderoncologie BV, Netherlands
- Runs
- 1 October 2026 to 30 September 2030
- Status
- Running
- EU funding
- €4.8m
- Total cost
- —
- Partners
- 33 organisations in 12 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101309891
What the project is doing
In the project's own words, from its summary on CORDIS.
In the era of precision medicine, we face a startling paradox: while sequencing entire genomes is routine, we remain blind to thousands of small open reading frames (smORFs) encoding microproteins that constitute a vast dark proteome. Recent breakthroughs have revealed their critical roles in diverse biological processes. This previously overlooked layer represents a fundamental gap in our understanding of cellular function and a major untapped source of therapeutic opportunities.
Despite growing recognition by initiatives like Cancer Research UK Grand Challenges, the field remains critically immature with fragmented research, non-standardized methodologies, and most critically, an acute shortage of scientists with multidisciplinary expertise. This human capital bottleneck prevents Europe from establishing leadership. ORFeus addresses this by training 15 interdisciplinary scientists bridging computational biology, proteogenomics, and therapeutic development.
Our consortium unites 15 leading European academics with 14 strategic industry partners spanning technology pioneers, AI innovators, and pharmaceutical developers. Through mandatory integrated training, industry secondments, and cutting-edge technologies, every researcher becomes both computationally and experimentally proficient, a crucial 'bilingual' skillset currently unavailable through traditional programs. The program delivers groundbreaking innovations: AI-powered prediction tools, standardized workflows through the open-access ORFeome platform, and novel cancer immunotherapy targets.
By creating Europe's first comprehensive dark proteome training program, ORFeus transforms this fragmented field into a mature research domain. Our graduates will drive innovation across academia and biotechnology, translate discoveries into clinical applications, and secure Europe's leadership in illuminating this vast unexplored dimension of human biology with profound implications for precision medicine.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Prinses Maxima Centrum Voor Kinderoncologie BV | Utrecht | Netherlands | Coordinator |
| Boehringer Ingelheim Rcv GmbH & Co Kg | Wien | Austria | Associatedpartner |
| Universiteit Gent | Gent | Belgium | Participant |
| myNeo | Gent | Belgium | Associatedpartner |
| Universite De Lausanne | Lausanne | Switzerland | Participant |
| Albert-Ludwigs-Universitaet Freiburg | Freiburg | Germany | Participant |
| Bruker Daltonics GmbH & Co Kg | Bremen | Germany | Associatedpartner |
| Curevac AG | Tubingen | Germany | Associatedpartner |
| European Molecular Biology Laboratory | Heidelberg | Germany | Associatedpartner |
| Humboldt-Universitaet Zu Berlin | Berlin | Germany | Associatedpartner |
| Max Delbrueck Centrum Fuer Molekulare Medizin in Der Helmholtz-Gemeinschaft (mdc) | Berlin | Germany | Participant |
| Immudex Aps | Virum | Denmark | Associatedpartner |
| Fundacio Institut Hospital Del Mar D Investigacions Mediques | Barcelona | Spain | Participant |
| Universidad Pompeu Fabra | Barcelona | Spain | Associatedpartner |
| EIRNA Bio Ltd | Cork | Ireland | Associatedpartner |
| University College Cork - National University of Ireland, Cork | Cork | Ireland | Participant |
| Immagina Biotechnology SRL | Trento | Italy | Associatedpartner |
| Erasmus Universitair Medisch Centrum Rotterdam | Rotterdam | Netherlands | Associatedpartner |
| Koninklijke Nederlandse Akademie Van Wetenschappen - Knaw | Amsterdam | Netherlands | Participant |
| Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis | Amsterdam | Netherlands | Participant |
| Stichting Oncode Institute | Utrecht | Netherlands | Associatedpartner |
| Universiteit Utrecht | Utrecht | Netherlands | Associatedpartner |
| Universitetet I Oslo | Oslo | Norway | Participant |
| Enara Bio Limited | Oxford | United Kingdom | Associatedpartner |
| Institute of Cancer Research: the Royal Cancer Hospital Lbg | London | United Kingdom | Participant |
| Oxford Nanopore Technologies Ltd | Oxford | United Kingdom | Associatedpartner |
| University of Dundee | Dundee | United Kingdom | Participant |
| University of Leeds | Leeds | United Kingdom | Participant |
| University of London | London | United Kingdom | Associatedpartner |
| University of Southampton | Southampton | United Kingdom | Participant |
| Genentech Inc | South San Francisco Ca | United States | Associatedpartner |
| ProFound Therapeutics, Inc. | Cambridge | United States | Associatedpartner |
| Tesorai Inc | San Diego | United States | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI